Biosplice Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2008)

Organization Overview

First Clinical Trial
2014
NCT02095548
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Biosplice Therapeutics, Inc. | Samumed LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 3)

Alopecia Areata (Phase 3)

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Intervertebral Disc Degeneration (Phase 1)

Liver Neoplasms (Phase 1)

Neoplasms (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pancreatic Neoplasms (Phase 1)

Pulmonary Fibrosis (Phase 2)

Respiratory Aspiration (Phase 2)

Spinal Diseases (Phase 1)

Tendinopathy (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 12